HK Stock Market Move | AKESO (09926) rose more than 7% in early trading, and the indication for colon cancer for the drug Kadcyla has been approved for clinical use.

AKESO (09926) rose more than 7% in the morning session and, as of the time of writing, was up 5.04% at HK$120.8, with a trading volume of HK$690 million. According to information from the CDE official website, AKESO's application for clinical trials of the anti-PD-1/CTLA-4 bispecific antibody drug, AK104, for neoadjuvant/adjuvant therapy of resectable highly microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer has received implied approval. This means that this globally pioneering PD-1/CTLA-4 bispecific antibody drug is formally making an impact in the perioperative treatment of colon cancer. It is reported that the anti-PD-1/CTLA-4 bispecific tumor immunotherapy drug, AK104, is a globally pioneering drug. In June 2022, AK104 was first approved for marketing for the treatment of recurrent or metastatic cervical cancer patients who had previously failed platinum-based chemotherapy, filling a gap in immune therapy for advanced cervical cancer in China. As of now, the intravenous infusion of AK104 has been approved for three indications domestically.